Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27870558 | 0.98 | TLR8 (0.68) | TLR8KDM4EUSP2ALDH1A1GLA | |
| SCHEMBL28793625 | 0.98 | TLR8 (0.68) | TLR8KDM4EUSP2ALDH1A1GLA | |
| SCHEMBL28162401 | 0.95 | TLR8 (0.69) | TLR8ALDH1A1GLAMAPTHPGD | |
| SCHEMBL28214718 | 0.90 | TLR8 (0.62) | TLR8ALDH1A1GLAMAPTHPGD | |
| SCHEMBL1325776 | 0.89 | TLR8 (0.60) | TLR8 | |
| SCHEMBL1325742 | 0.89 | TLR8 (0.64) | TLR8 | |
| SCHEMBL1326148 | 0.89 | TLR8 (0.60) | TLR8KDM4EUSP2ALDH1A1GLA | |
| SCHEMBL28146814 | 0.87 | TLR8 (0.62) | TLR8ALDH1A1GLAMAPTHPGD | |
| Formamide SCHEMBL28501493 | 0.86 | TLR8 (0.62) | TLR8ALDH1A1GAA | |
| SCHEMBL28609423 | 0.84 | TLR8 (0.54) | TLR8KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114572-A1 | USE OF COMPOUND IN PREPARATION OF DRUG FOR TREATMENT OR PREVENTION OF MYCOBACTERIUM TUBERCULOSIS INFECTION | 丹诺医药(苏州）有限公司 | 2024-06-06 | — | — | WO | claimed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | claimed |
| EP-4312978-A2 | COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS | TRX Biosciences Limited (GB) | 2024-02-07 | — | — | EP | claimed |
| WO-2023191725-A2 | ANTI-TUBERCULAR COMPOSITIONS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-10-05 | — | — | WO | claimed |
| WO-2023156648-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-24 | — | — | WO | claimed |
| CN-110997651-B | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-110804016-B | Diaryl quinoline derivatives against mycobacterium tuberculosis | 福建省微生物研究所 | 2022-11-04 | — | — | CN | claimed |
| CN-110997680-B | Novel compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-10-21 | — | — | CN | claimed |
| US-11253499-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| US-11254689-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| WO-2019034700-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | claimed |
| WO-2019034729-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | claimed |
| WO-2018206466-A1 | SANFETRINEM OR A SALT OR ESTER THEREOF FOR USE IN TREATING MYCOBACTERIAL INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-11-15 | — | — | WO | claimed |
| WO-2017190043-A1 | CEPHALOSPORIN-TYPE COMPOUNDS | UNIVERSITY OF KANSAS (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170136102-A1 | PHAGE-DERIVED COMPOSITIONS FOR IMPROVED MYCOBACTERIAL THERAPY | BACTOCLEAR HOLDINGS PTE. LTD. (SG) | 2017-05-18 | — | — | US | claimed |
| WO-2015145463-A1 | PHAGE-DERIVED COMPOSITIONS FOR IMPROVED MYCOBACTERIAL THERAPY | GANGAGEN, INC. (US) | 2015-10-01 | — | — | WO | claimed |
| EP-2475365-A1 | COMPOSITIONS OF N-BENZYL-3-(4-CHLOROPHENYL)-2-[METHYL-[2-OXO-2-(3,4,5-TRIMETHOXYPHENYL) ACETYL]AMINO]-N-[3-(4-PYRI(DYL)-1-[2-[4-PYRIDYL)ETHYL]PROPYL]PROPANAMIDE AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2012-07-18 | — | — | EP | claimed |
| WO-2011139832-A2 | METHOD FOR TREATING MYCOBACTERIAL INFECTIONS | RIB-X PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | claimed |
| WO-2011031926-A1 | COMPOSITIONS OF N-BENZYL-3-(4-CHLOROPHENYL)-2-[METHYL-[2-OXO-2-(3,4,5-TRIMETHOXYPHENYL) ACETYL]AMINO]-N-[3-(4-PYRIDYL)-1-[2-[4-PYRIDYL)ETHYL]PROPANAMIDE AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-17 | — | — | WO | claimed |
| US-20110065723-A1 | COMPOSITIONS OF N-BENZYL-3-(4-CHLOROPHENYL)-2-[METHYL-[2-OXO-2-(3,4,5-TRIMETHOXYPHENYL)ACETYL]AMINO]-N-[3-(4-PYRIDYL)-1-[2-(4-PYRIDYL)ETHYL]PROPYL]PROPANAMIDE AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253499-B2 | Compounds | SDHA, SDHB, FDPS | TLR8 2147/4885KDM4E 4043/4885USP2 4632/4885 |
| US-20110065723-A1 | COMPOSITIONS OF N-BENZYL-3-(4-CHLOROPHENYL)-2-[METHYL-[2-OXO-2-(3,4,5-TRIMETHOXYPHENYL)ACETYL]AMINO]-N-[3-(4-PYRIDYL)-1-[2-(4-PYRIDYL)ETHYL]PROPYL]PROPANAMIDE AND USES THEREOF | CBR3, B3GNT2, NAA15 | TLR8 1533/4885KDM4E 630/4885USP2 2487/4885 |
| US-11254689-B2 | Compounds | SDHA, SDHB, FDPS | TLR8 2147/4885KDM4E 4043/4885USP2 4632/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | TLR8 2147/4885KDM4E 4043/4885USP2 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.